北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 淋巴肿瘤内科  > 期刊论文
学科主题: 临床医学
题名:
Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment
作者: Zheng, Xiaohui; Ding, Ning; Song, Yuqin; Feng, Lixia; Zhu, Jun
关键词: Germinal center B cell-like diffuse large B cell lymphoma ; Bruton&prime ; s tyrosine kinase ; BCR ; Apoptosis
刊名: CANCER CELL INTERNATIONAL
发表日期: 2014-04-03
DOI: 10.1186/1475-2867-14-32
卷: 14
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: CHRONIC LYMPHOCYTIC-LEUKEMIA ; BRUTON TYROSINE KINASE ; RITUXIMAB THERAPY ; PROTEIN-KINASE ; ACTIVATION ; SURVIVAL ; EXPRESSION ; INHIBITORS ; PCI-32765 ; MALIGNANCIES
英文摘要:

Background: Although rituximab in the combination of CHOP chemotherapy has been widely used as the standard treatment for several kinds of B-cell non-Hodgkin lymphoma (B-NHL), a great number of B-NHL patients treated with this immunotherapy still develop primary and secondary resistance. Recently Bruton′s tyrosine kinase (Btk) inhibitor ibrutinib showed promising therapeutic effect in relapsed/refractory CLL and B-cell NHL, which provided essential alternatives for these patients.

Methods: The proliferation and apoptosis induction of tumor cells were measured by cell viability assay and Annexin-V staining. Western Blotting analysis and real-time PCR were used to detect the expression level of target proteins and chemokines production.

Results: We demonstrated that ibrutinib inhibited the proliferation and induced apoptosis of GCB-DLBCL cell lines through suppression of BCR signaling pathway and activation of caspase-3. Furthermore, the chemokines CCL3 and CCL4 production from tumor cells were also found to be attenuated by ibrutinib treatment. But different cell lines exhibited distinct sensitivity after ibrutinib treatment. Interestingly, the decreasing level of p-ERK after ibrutinib treatment, but not the basal expression level of Btk, correlated with different drug sensitivity.

Conclusions: Ibrutinib could be a potentially useful therapy for GCB-DLBCL and the decreasing level of p-ERK could become a useful biomarker to predict related therapeutic response.

语种: 英语
所属项目编号: 81201873 ; 81241073 ; 7132050
项目资助者: NSFC ; Beijing Natural Science Foundation ; "985" Basic Research Fund from Peking University
WOS记录号: WOS:000334625400001
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/52469
Appears in Collections:北京大学临床肿瘤学院_淋巴肿瘤内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China

Recommended Citation:
Zheng, Xiaohui,Ding, Ning,Song, Yuqin,et al. Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment[J]. CANCER CELL INTERNATIONAL,2014,14.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zheng, Xiaohui]'s Articles
[Ding, Ning]'s Articles
[Song, Yuqin]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zheng, Xiaohui]‘s Articles
[Ding, Ning]‘s Articles
[Song, Yuqin]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace